PRO-1184 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PRO-1184’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRO-1184 is under development for the treatment of solid tumors such as non small cell lung cancer, ovarian cancer, endometrial cancer, breast cancer (HER2 negative breast cancer, primary peritoneal cancer, fallopian tube cancer, malignant mesothelioma, triple-negative breast cancer and unspecified indication. It is an antibody drug conjugate (ADC),conjugated to the exatecan payload via a novel hydrophilic linker. It acts by targeting folate receptor alpha. It is administered through intravenous route.
ProfoundBio Suzhou overview
ProfoundBio Suzhou (ProfoundBio) discovers and develops antibody-drug conjugates and T-cell engagers for the treatment of cancer. The company is investigating PRO1184, a FOLR1 (folate receptor alpha) based antibody targeting solid tumors; and PRO1160 to treat renal cell cancer (RCC) and non-Hodgkin lymphoma (NHL) cancer. It is also evaluating PRO1107, PRO1109, PRO1135, PRO1173, PRO1103, PRO1106 and PRO1176 programs against solid tumors. The company focuses on developing drugs that deliver small molecule payloads to tumor cells and eradicate cancer by supporting the immune system. ProfoundBio is headquartered in Suzhou, Jiangsu, China.
For a complete picture of PRO-1184’s drug-specific PTSR and LoA scores, buy the report here.